SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04154956|
Recruitment Status : Recruiting
First Posted : November 7, 2019
Last Update Posted : May 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS])
- Study success is defined either on PFS or OS
- The primary objective is to determine whether tusamitamab ravtansine improves the progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous non-small-cell lung cancer (NSCLC) expressing CEACAM5 greater than or equal to 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI)
- The primary objective is to determine whether tusamitamab ravtansine improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 greater than or equal to 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
- To compare the objective response rate (ORR) of tusamitamab ravtansine with docetaxel
- To compare the health-related quality of life (HRQOL) of tusamitamab ravtansine with docetaxel
- To evaluate the safety of tusamitamab ravtansine compared to docetaxel
- To assess the duration of response (DOR) of tusamitamab ravtansine as compared with docetaxel
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer Metastatic||Drug: SAR408701 Drug: Docetaxel||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||450 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors|
|Actual Study Start Date :||January 12, 2017|
|Estimated Primary Completion Date :||July 11, 2024|
|Estimated Study Completion Date :||August 16, 2024|
Experimental: SAR408701 (tusamitamab ravtansine)
Administered intravenously once every 2 weeks
Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
Active Comparator: Docetaxel
Administered intravenously once every 3 weeks
Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
Other Name: TAXOTERE
- Progression free survival (PFS) [ Time Frame: Baseline to up to approximately 15 months ]PFS will be defined as the time from randomization to the date of the first documented disease progression or death of any cause, whichever comes first.
- Overall Survival (OS) [ Time Frame: Baseline up to approximately 2 years ]OS will be defined as the time of randomization to the date of death due to any cause.
- Objective response rate (ORR) [ Time Frame: Baseline up to approximately 2 years ]Objective response rate will be defined as the proportion of participants who have a complete response (CR) or partial response (PR), as best overall response derived from Overall Response (OR) determined by the Independent Radiology Review Committee (IRC) per Response Evaluation Criteria in Solid Tumor (RECIST) 1.1
- Health related quality of life (HRQOL) - disease related symptoms [ Time Frame: Baseline up to median 12 months ]Time to deterioration (TTD) in disease related symptoms as determined by European Organization for Research and Treatment for Cancer (EORTC)- Quality of life Questionnaire (QLQ)-Lung Cancer (LC)13
- Health related quality of life (HRQOL) - physical function [ Time Frame: Baseline up to median 12 months ]TTD in physical function as determined by EORTC QLQ C30
- Health related quality of life (HRQOL) - role function [ Time Frame: Baseline up to median 12 months ]TTD in role function as determined by EORTC QLQ C30
- Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) [ Time Frame: Baseline up to end of study (approximately 2 years) ]Incidence of TEAEs and SAEs and laboratory abnormalities according to NCI CTCAE V5
- Duration of response (DOR) [ Time Frame: Baseline up to approximately 2 years ]Duration of response (DOR) is defined as the time from first documented evidence of complete response (CR) or partial response (PR) until progressive disease (PD) determined per RECIST 1.1 or death from any cause, whichever occurs first.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- At least 18 years of age or above (or country's legal age of maturity if above 18 years) and signed the informed consent.
- Histologically or cytologically proven diagnosis of non-squamous NSCLC with metastatic disease at study entry; progression after platinum-based chemotherapy and immune checkpoint inhibitor.
- Participants with carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 5 expression of greater than or equal to 2+ in archival tumor sample (or if not available, fresh biopsy sample) involving at least 50% of the tumor cell population as demonstrated prospectively by central laboratory via immune histochemistry (IHC).
- At least one measurable lesion by RECIST v1.1 as determined by local site investigator /radiologist assessment.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- A female participant who agrees to use highly effective contraceptive methods during and for at least 7 months after the last dose of study intervention.
- A male participant who agrees to use highly effective contraception methods during and for at least 6 months after the last dose of study intervention.
- Patients with untreated brain metastases and history of leptomeningeal disease. if previously treated brain metastases no documentation of non-progressive disease in brain by imaging performed at least 4 weeks after CNS directed treatment and at least 2 weeks prior to the first dose of study intervention.
- Significant concomitant illnesses, including all severe medical conditions that would impair the patient's participation in the study or interpretation of the results.
- History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
- Non-resolution of any prior treatment related toxicity to less than grade 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (V) 5.0, except for alopecia, vitiligo and active thyroiditis controlled with hormonal replacement therapy
- History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or unresolved viral hepatitis
- Previous history of and/or unresolved corneal disorders. The use of contact lenses is not permitted.
- Concurrent treatment with any other anticancer therapy.
- Prior treatment with docetaxel or maytansinoid derivatives (DM1 or DM4 antibody drug conjugate) or any drug targeting CEACAM5.
- Contraindication to use of corticosteroid premedication.
- Previous enrollment in this study and current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
- Poor bone marrow, liver or kidney functions
- Hypersensitivity to any of the study interventions, or components thereof (EDTA), or drug (paclitaxel, polysorbate 80) or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04154956
|Contact: Trial Transparency email recommended (Toll free number for US & Canada)||800-633-1610 ext option 6||Contact-US@sanofi.com|
|Study Director:||Clinical Sciences & Operations||Sanofi|
|Other Study ID Numbers:||
2019-001273-81 ( EudraCT Number )
U1111-1233-0781 ( Registry Identifier: ICTRP )
|First Posted:||November 7, 2019 Key Record Dates|
|Last Update Posted:||May 8, 2023|
|Last Verified:||May 5, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Molecular Mechanisms of Pharmacological Action